A Scoping Review of Clinical Trials on the Expanding Role of Beta‑Blockers in Dermatology

Summary Beta‐blockers have been proven to be safe and effective treatments for various medical conditions, but their full potential in dermatology remains to be fully understood. We conducted a comprehensive review of clinical trials published between January 2000 and August 2025. 41 studies were included, exploring the use of beta‐blockers for any dermatological conditions, involving over 4,000 people worldwide. Our findings show strong evidence that beta‐blockers are the first‐line treatment for infantile hemangiomas. Additionally, they reduce mortality in patients with burns, accelerate wound healing in chronic venous and diabetic ulcers, and improve skin graft donor sites. Emerging data suggest benefits in rosacea, pyogenic granulomas, post‑procedural erythema, and as an adjunct to immune checkpoint inhibitors in melanoma, alongside a favorable safety profile in clinical trials. However, beta‑blockers can exacerbate inflammatory dermatoses, may interfere with the management of anaphylaxis, and exert complex effects on cutaneous immunity. Overall, beta‑blockers are evolving into versatile dermatologic tools whose expanding indications must be balanced against their immunologic and cardiovascular risks, and further high‑quality trials are needed to standardize their use in these emerging applications.